SE405806B - Forfarande for framstellning av urokinas-heparinkomplex - Google Patents
Forfarande for framstellning av urokinas-heparinkomplexInfo
- Publication number
- SE405806B SE405806B SE7212220A SE1222072A SE405806B SE 405806 B SE405806 B SE 405806B SE 7212220 A SE7212220 A SE 7212220A SE 1222072 A SE1222072 A SE 1222072A SE 405806 B SE405806 B SE 405806B
- Authority
- SE
- Sweden
- Prior art keywords
- urokinase
- heparin
- solution
- complex
- urokinas
- Prior art date
Links
- 229960002897 heparin Drugs 0.000 title claims description 47
- 229920000669 heparin Polymers 0.000 title claims description 47
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 title claims description 21
- 238000000034 method Methods 0.000 title claims description 9
- 229960005356 urokinase Drugs 0.000 claims description 57
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 56
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 56
- 230000000694 effects Effects 0.000 claims description 27
- 239000002244 precipitate Substances 0.000 claims description 12
- 238000001802 infusion Methods 0.000 claims description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 10
- 239000008103 glucose Substances 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 9
- 210000002966 serum Anatomy 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 239000003527 fibrinolytic agent Substances 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- 238000002474 experimental method Methods 0.000 claims description 3
- 210000002700 urine Anatomy 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 229960000103 thrombolytic agent Drugs 0.000 claims description 2
- 238000010968 computed tomography angiography Methods 0.000 claims 5
- 230000010412 perfusion Effects 0.000 claims 4
- 230000003480 fibrinolytic effect Effects 0.000 claims 1
- 238000011065 in-situ storage Methods 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 description 51
- 238000005119 centrifugation Methods 0.000 description 10
- 239000005995 Aluminium silicate Substances 0.000 description 9
- 235000012211 aluminium silicate Nutrition 0.000 description 9
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 9
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000001914 filtration Methods 0.000 description 7
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 5
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 5
- 235000011130 ammonium sulphate Nutrition 0.000 description 5
- 210000001367 artery Anatomy 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000003978 infusion fluid Substances 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 239000001166 ammonium sulphate Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920004934 Dacron® Polymers 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229930186657 Lat Natural products 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000282806 Rhinoceros Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229910052573 porcelain Inorganic materials 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000012209 synthetic fiber Substances 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 201000005060 thrombophlebitis Diseases 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7134435A FR2153200A1 (en) | 1971-09-24 | 1971-09-24 | Stable,pyrogen-free urokinase prepns - from human urine |
| FR7223867A FR2190412A1 (en) | 1972-06-30 | 1972-06-30 | Stable,pyrogen-free urokinase prepns - from human urine |
| FR7223868A FR2190413A2 (en) | 1972-06-30 | 1972-06-30 | Stable,pyrogen-free urokinase prepns - from human urine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SE405806B true SE405806B (sv) | 1979-01-08 |
Family
ID=27249660
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE7212220A SE405806B (sv) | 1971-09-24 | 1972-09-21 | Forfarande for framstellning av urokinas-heparinkomplex |
| SE7514792A SE7514792L (sv) | 1971-09-24 | 1975-12-30 | Forfarande for framstellning av urokinas |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE7514792A SE7514792L (sv) | 1971-09-24 | 1975-12-30 | Forfarande for framstellning av urokinas |
Country Status (11)
| Country | Link |
|---|---|
| JP (1) | JPS5718465B2 (en)van) |
| BE (1) | BE789189A (en)van) |
| CA (1) | CA986013A (en)van) |
| CH (2) | CH604726A5 (en)van) |
| DE (1) | DE2246969C2 (en)van) |
| DK (1) | DK133130C (en)van) |
| ES (3) | ES406980A1 (en)van) |
| GB (2) | GB1411421A (en)van) |
| IN (1) | IN141112B (en)van) |
| NL (1) | NL7212891A (en)van) |
| SE (2) | SE405806B (en)van) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2428248B2 (de) * | 1973-07-24 | 1978-01-12 | Serna Ag, Glarus (Schweiz) | Verfahren zur herstellung von pyrogenfreier urokinase |
| US3957582A (en) * | 1974-11-20 | 1976-05-18 | Abbott Laboratories | Purification of urokinase |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3256158A (en) * | 1963-03-22 | 1966-06-14 | Abbott Lab | Purification of urokinase |
| US3355361A (en) * | 1964-10-15 | 1967-11-28 | Sterling Drug Inc | Recovery and purification of urokinase |
| US3477912A (en) * | 1967-07-07 | 1969-11-11 | Century Lab Inc | Method of production of urokinase |
| US3477913A (en) * | 1967-10-31 | 1969-11-11 | Century Lab Inc | Method of production of urokinase |
-
0
- BE BE789189D patent/BE789189A/xx not_active IP Right Cessation
-
1972
- 1972-09-21 SE SE7212220A patent/SE405806B/sv unknown
- 1972-09-22 NL NL7212891A patent/NL7212891A/xx active Search and Examination
- 1972-09-22 DK DK470672A patent/DK133130C/da not_active IP Right Cessation
- 1972-09-22 JP JP9561172A patent/JPS5718465B2/ja not_active Expired
- 1972-09-22 GB GB4400372A patent/GB1411421A/en not_active Expired
- 1972-09-22 GB GB1550275A patent/GB1411422A/en not_active Expired
- 1972-09-22 CH CH1715974A patent/CH604726A5/xx not_active IP Right Cessation
- 1972-09-22 CA CA152,328A patent/CA986013A/en not_active Expired
- 1972-09-22 CH CH1384072A patent/CH560050A5/xx not_active IP Right Cessation
- 1972-09-23 ES ES406980A patent/ES406980A1/es not_active Expired
- 1972-09-25 DE DE2246969A patent/DE2246969C2/de not_active Expired
-
1973
- 1973-09-17 IN IN2122/CAL/1973A patent/IN141112B/en unknown
-
1975
- 1975-08-14 ES ES440244A patent/ES440244A1/es not_active Expired
- 1975-12-30 SE SE7514792A patent/SE7514792L/xx unknown
-
1977
- 1977-02-16 ES ES455975A patent/ES455975A1/es not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| JPS4856888A (en)van) | 1973-08-09 |
| CH604726A5 (en)van) | 1978-09-15 |
| BE789189A (fr) | 1973-03-22 |
| GB1411422A (en) | 1975-10-22 |
| ES406980A1 (es) | 1976-06-16 |
| SE7514792L (sv) | 1975-12-30 |
| CA986013A (en) | 1976-03-23 |
| GB1411421A (en) | 1975-10-22 |
| DE2246969C2 (de) | 1986-12-11 |
| DK133130B (da) | 1976-03-29 |
| ES440244A1 (es) | 1977-08-01 |
| NL7212891A (en)van) | 1973-03-27 |
| CH560050A5 (en)van) | 1975-03-27 |
| DK133130C (da) | 1976-09-27 |
| IN141112B (en)van) | 1977-01-22 |
| DE2246969A1 (de) | 1973-04-05 |
| ES455975A1 (es) | 1978-03-01 |
| JPS5718465B2 (en)van) | 1982-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hirsh et al. | Heparin kinetics in venous thrombosis and pulmonary embolism. | |
| Gralnick et al. | Heparin treatment for the hemorrhagic diathesis of acute promyelocytic leukemia | |
| Thomas et al. | Gold-Precipitation by Heparin of a Protein in Rabbit and Human Plasma | |
| Rabiner et al. | The role of intravascular haemolysis and the reticulo‐endothelial system in the production of a hypercoagulable state | |
| Lefer et al. | Relationship of plasma peptides to the myocardial depressant factor in hemorrhagic shock in cats | |
| Jandorf et al. | Distribution of radiophosphorus in rabbit tissues after injection of phosphorus-labeled diisopropyl fluorophosphate | |
| Bell et al. | The effect of arvin on blood coagulation factors | |
| Howell et al. | Effect of protein binding on levels of ampicillin and cloxacillin in synovial fluid | |
| DE69006851T2 (de) | Blutgerinnungshemmende zusammensetzungen aus faktor xa. | |
| White et al. | Synergistic toxicity of endotoxin and hemoglobin | |
| FR2497229A1 (fr) | Procede de preparation d'un derive polysaccharidique de fibrinolysine | |
| NURMOHAMED et al. | Long-term Efficacy and Safety of a Low Molecular Weight Heparin in Chronic Hemodialysis Patients A Comparison with Standard Heparin | |
| JPH01500997A (ja) | ヒアルロニダーゼの使用 | |
| JPS595164A (ja) | 放射性コンプレツクス | |
| US4029767A (en) | Pharmaceutical compositions of stable urokinase-heparin complexes and methods for use thereof | |
| US4106992A (en) | Purification of urokinase | |
| Cattell | Focal mesangial proliferative glomerulonephritis in the rat caused by Habu snake venom: the role of platelets | |
| SE405806B (sv) | Forfarande for framstellning av urokinas-heparinkomplex | |
| Gans | Thrombogenic properties of epsilon amino caproic acid | |
| McCullough et al. | Rapid plasma exchange with the continuous flow centrifuge | |
| Canaud et al. | Prostacyclin (epoprostenol) as the sole antithrombotic agent in postdilutional hemofiltration | |
| Bruning et al. | Prothrombal: a new concentrate of human prothrombin complex for clinical use | |
| EP0020780A1 (en) | Fibrinolytic material and process for producing same | |
| JPH0454651B2 (en)van) | ||
| JPS61267524A (ja) | フィブリン親和性ウロキナーゼ複合体含有血栓溶解剤 |